Anthem Biosciences
ANTHEMNSE

Anthem Biosciences

₹799.050.00 (0.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
775.85
Today’s high
810.00
52 week low
579.15
52 week high
873.50
Open price
784.00
Previous close
799.05
Live volume
--
Lower circuit
639.25
Upper circuit
958.85

Fundamentals

Market Cap
₹44,954Cr
ROE
18.75%
P/E Ratio(TTM)
92.73
EPS(TTM)
8.63
P/B Ratio
16.33
Dividend Yield
0.00%
Industry P/E
34.42
Book Value
49.00
Debt to Equity
0.04
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹457
-23.67%
Profit (Cr)
₹92.82
-46.48%
0150300450600
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Revenue growthValue
1Y (TTM)-13%
3Y CAGR+15%
Profit growthValue
1Y (TTM)-25%
3Y CAGR+4%

About

Anthem Biosciences Limited is a contract research and manufacturing services (CRAMS) organization serving pharmaceutical and biotechnology companies.;
CEO/MD
Ajay Bhardwaj
Founded in
2006
NSE symbol
ANTHEM

Shareholding Pattern

Dec '24
Jul '25
Sep '25
Dec '25
Mar '26
Promoters
74.68%
Mutual Funds
10.12%
Retail And Others
9.76%
Foreign Institutions
4.02%
Other Domestic Institutions
1.42%
Livesquawk
Citigroup rates Anthem Biosciences Buy, targets ₹870 for its CRDMO growth. Firm expects 26% FY23-26 revenue CAGR and 22% EBITDA CAGR FY26-28.
Livesquawk
Anthem Biosciences' Q3 EBITDA stood at 1.57B, down from 1.6B YoY. EBITDA margin improved to 37.2% from 32.0% YoY, reflecting better profitability.
2026
5
Feb
Quarterly Result
Release date
2025
8
Nov
Quarterly Result
Release date
13
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks